Taysha Gene TherapiesTSHA
TSHA
About: Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Employees: 73
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,957% more call options, than puts
Call options by funds: $144K | Put options by funds: $7K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
23% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 31
0.18% less ownership
Funds ownership: 81.53% [Q4 2024] → 81.35% (-0.18%) [Q1 2025]
8% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 25
2% less funds holding
Funds holding: 128 [Q4 2024] → 125 (-3) [Q1 2025]
20% less capital invested
Capital invested by funds: $289M [Q4 2024] → $232M (-$57.2M) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
136%
upside
Avg. target
$8.20
223%
upside
High target
$11
333%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Needham Gil Blum | 215%upside $8 | Buy Reiterated | 10 Jun 2025 |
Canaccord Genuity Whitney Ijem | 333%upside $11 | Buy Maintained | 3 Jun 2025 |
JMP Securities Silvan Tuerkcan | 136%upside $6 | Market Outperform Maintained | 29 May 2025 |
Chardan Capital Geulah Livshits | 254%upside $9 | Buy Maintained | 29 May 2025 |
Cantor Fitzgerald Kristen Kluska | 176%upside $7 | Overweight Reiterated | 28 Apr 2025 |
Financial journalist opinion
Based on 6 articles about TSHA published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 2, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 401,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 week ago
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
Recently disclosed clinical cohort data from high (1x10 15 total vg) and low dose (5.7x10 14 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials
Positive
Benzinga
2 weeks ago
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?
Taysha Gene Therapies Inc. TSHA on Wednesday announced details of its planned pivotal Part B trial design for TSHA-102 following written alignment from the U.S. Food and Drug Administration (FDA).
Neutral
GlobeNewsWire
2 weeks ago
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 46,868,687 shares of its common stock at a price to the public of $2.75 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 25,858,586 shares of its common stock at an offering price of $2.749 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 10,909,090 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about May 30, 2025, subject to customary closing conditions.
Neutral
GlobeNewsWire
2 weeks ago
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions (including shares underlying the pre-funded warrants). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Neutral
GlobeNewsWire
2 weeks ago
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102
Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of Rett syndrome
Neutral
Seeking Alpha
1 month ago
Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Hayleigh Collins - Senior Director, Corporate Communications and Investor Relations Sean P. Nolan - Chief Executive Officer Sukumar Nagendran - President and Head of R&D Kamran Alam - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Gil Blum - Needham and Company Maury Raycroft - Jefferies Yanan Zhu - Wells Fargo Biren Amin - Piper Sandler Whitney Ijem - Canaccord Genuity Jack Allen - Baird Joon Lee - Truist Securities Silvan Tuerkcan - Citizens Malcolm Hoffman - BMO Capital Markets Operator Greetings, and welcome to the Taysha Gene Therapies First Quarter 2025 Earnings Call.
Neutral
Zacks Investment Research
1 month ago
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update
Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and associated statistical analysis plan as an amendment to the IND application, eliminating the need for formal end-of-phase meeting and potentially expediting study initiation and registration; IND amendment submission expected in Q2 2025 High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of April 10, 2025, data cutoff Program update on pivotal trial design, Rett syndrome natural history data analysis and clinical data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials expected in Q2 2025 in conjunction with IRSF Rett Syndrome Scientific Meeting Conference call and live webcast today at 8:30 AM Eastern Time DALLAS, May 15, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or the “Company”), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. “We are pleased with the significant regulatory and clinical progress across our TSHA-102 program in clinical evaluation for children, adolescents and adults suffering from Rett syndrome.
Neutral
GlobeNewsWire
1 month ago
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15
DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2025, and host a corporate update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM Eastern Time.
Charts implemented using Lightweight Charts™